EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+11.92%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$148M
AUM Growth
+$148M
(+32%)
Cap. Flow
+$29.1M
Cap. Flow
% of AUM
19.64%
Top 10 Holdings %
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$5.27M |
| 2 |
Align Technology
ALGN
|
$4.76M |
| 3 |
Gilead Sciences
GILD
|
$4.19M |
| 4 |
Geron
GERN
|
$4.11M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$5.2M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$4.02M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
$3.84M |
| 4 |
Travere Therapeutics
TVTX
|
$3.64M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$3.03M |
Sector Composition
| 1 | Healthcare | 98.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
VYNE Therapeutics
VYNE
$8.09M
| $664K | 0.45% |
353,434
| – | – |
|
|
SYRS
52
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $642K | 0.43% |
298,575
+139,400
| +88% | +$300K |
|
|
ADAG
53
Adagene
ADAG
$103M
| $583K | 0.39% |
262,625
+111,749
| +74% | +$248K |
|
54
Gossamer Bio
GOSS
$587M
| $462K | 0.31% |
468,499
-659,200
| -58% | -$650K |
|
55
Aprea Therapeutics
APRE
$8.91M
| $377K | 0.26% |
137,174
| – | – |
|
|
PROC
56
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
| $280K | 0.19% |
126,901
| – | – |
|
57
Leap Therapeutics
LPTX
$12M
| $264K | 0.18% |
+102,631
| New | +$264K |
|
58
Pacific Biosciences
PACB
$378M
| $128K | 0.09% |
75,300
| – | – |
|
59
AbCellera Biologics
ABCL
$1.19B
| – | – |
-514,900
| Closed | -$1.52M |
|
60
Arvinas
ARVN
$580M
| – | – |
-82,400
| Closed | -$2.19M |
|
61
Alphatec Holdings
ATEC
$2.35B
| – | – |
-162,100
| Closed | -$1.69M |
|
|
AUTL
62
Autolus Therapeutics
AUTL
$383M
| – | – |
-839,472
| Closed | -$2.92M |
|
|
AVDL
63
Avadel Pharmaceuticals
AVDL
$1.42B
| – | – |
-209,092
| Closed | -$2.94M |
|
64
Biohaven
BHVN
$1.71B
| – | – |
-57,800
| Closed | -$2.01M |
|
65
Cabaletta Bio
CABA
$144M
| – | – |
-300,200
| Closed | -$2.25M |
|
|
66
Corbus Pharmaceuticals
CRBP
$121M
| – | – |
-84,790
| Closed | -$3.84M |
|
67
DexCom
DXCM
$30.9B
| – | – |
-25,928
| Closed | -$2.94M |
|
|
ELEV
68
DELISTED
Elevation Oncology
ELEV
| – | – |
-369,322
| Closed | -$997K |
|
69
Fulcrum Therapeutics
FULC
$353M
| – | – |
-302,700
| Closed | -$1.88M |
|
70
HilleVax
HLVX
$105M
| – | – |
-18,000
| Closed | -$260K |
|
|
IMAB
71
I-MAB
IMAB
$380M
| – | – |
-271,400
| Closed | -$453K |
|
72
Masimo
MASI
$7.43B
| – | – |
-19,800
| Closed | -$2.49M |
|
|
73
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-10,800
| Closed | -$3.03M |
|
74
Merus
MRUS
$5.04B
| – | – |
-45,100
| Closed | -$2.67M |
|
75
PMV Pharmaceuticals
PMVP
$82.1M
| – | – |
-358,400
| Closed | -$581K |
|